September 2022 - Cancer Currents Blog
-
Teclistamab Shows Promise for People with Heavily Pretreated Multiple MyelomaIn a small clinical trial, nearly 40% of people with multiple myeloma who were treated with the immunotherapy drug teclistamab (Tecvayli) had all signs of their cancer disappear. The trial participants had myeloma that did not respond to or came back after three or more prior treatments.
-
Making Transformative Advances against Childhood Cancer: A Conversation with Dr. Doug HawkinsDr. Doug Hawkins, chair of the NCI-funded Children’s Oncology Group, discusses advances in treating children with cancer, COG’s role in conducting clinical trials, and efforts like the Childhood Cancer Data Initiative and Molecular Characterization Initiative.
-
Vulnerability in Brain Tumors May Open Door to New TreatmentsTwo companion studies have found different forms of some brain tumors, diffuse midline glioma and IDH-mutant glioma, become dependent for their survival on the production of chemicals called pyrimidines. Clinical trials are planned to test a drug that blocks pyrimidine synthesis in patients with gliomas.
-
New on NCI’s Websites for September 2022NCI periodically provides updates on new websites and other online content of interest to the cancer community. See selected content that has been added as of September 2022.
-
Enhertu Marks First Targeted Therapy for HER2-Mutant Lung CancerOn August 11, the Food and Drug Administration (FDA) gave accelerated approval to trastuzumab deruxtecan (Enhertu) for adults with non-small cell lung cancer (NSCLC) that has a specific mutation in the HER2 gene. Around 3% of people with NSCLC have this kind of HER2 mutation.
-
Study Confirms Dinutuximab Extends Life for Children with High-Risk NeuroblastomaResearchers have confirmed that the immunotherapy drug dinutuximab (Unituxin) can help children with high-risk neuroblastoma live longer. The finding is based on a trial of nearly 1,200 children with the disease.